[1. Lirov R, Else T, Lerario AM, Hammer GD. Adrenal Tumors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: principles & practice of oncology. 10h ed. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins; 2015.]Search in Google Scholar
[2. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors. Eur J Endocrin. 2016;175(2):G1-34.10.1530/EJE-16-046727390021]Search in Google Scholar
[3. Kumari NS, Sireesha A, Jayashree K, Kumar OS. Spectrum of histomorphological patterns of adrenal tumors: A one year study at Gandhi Hospital, Hyderabad - A tertiary referral centre. IAIM, 2016; 3(7): 77-86.]Search in Google Scholar
[4. Tang YZ, Bharwani N, Micco M, Akker S, Rockall AG, Sahdev A. The prevalence of incidentally detected adrenal enlargement on CT. Clin Radiol. 2014 Jan 31;69(1):e37-42.10.1016/j.crad.2013.08.01724161458]Search in Google Scholar
[5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8.10.2214/AJR.07.279918430826]Search in Google Scholar
[6. Reginelli A, Di Grezia G, Izzo A, et al, 2014 Imaging of adrenal incidentaloma: our experience. Int J Surg 12: Suppl 1: 126-31.10.1016/j.ijsu.2014.05.02924862667]Search in Google Scholar
[7. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, et al. AME position statement on adrenal incidentaloma. Eur J Endocrin. 2011;164(6):851-70.10.1530/EJE-10-114721471169]Search in Google Scholar
[8. Patel RD, Vanikar AV, Suthar KS, Kanodia KV. Primary Adrenal Tumors-Five Years Single Centre Experience. J Pathol. 2012;2(04):107.10.4236/ojpathology.2012.24020]Search in Google Scholar
[9. Morelli V, Palmieri S, Salcuni AS, et al. Bilateral and unilateral adrenal incidentalomas: biochemical and clinical characteristics. Eur J Endocrinol 2013;168:235–41.10.1530/EJE-12-077723169694]Search in Google Scholar
[10. Khanna S, Priya R, Bhartiya SK, Basu S, Shukla VK. Adrenal tumors: An experience of 10 years in a single surgical unit. Indian J Cancer. 2015;52(3):475.10.4103/0019-509X.17674926905175]Search in Google Scholar
[11. Naidu V, Singh B. Adrenal lesions encountered in current medical practice − a review of their radiological imaging. S Afr J Rad. 2013;17:128–38. DOI:10.7196/SAJR.914.10.7196/sajr.914]Open DOISearch in Google Scholar
[12. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E & Kharlip J. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009;15:1–20.10.4158/EP.15.S1.119632967]Open DOISearch in Google Scholar
[13. Sundin A. Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics. 2012;2:516-22.10.7150/thno.3613336455722737189]Search in Google Scholar
[14. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007 Sep;14(3):587-99.1791409010.1677/ERC-07-004517914090]Search in Google Scholar
[15. Maurea S, Mainenti PP, Ponsiglione A, Salvatore M. Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques. J Adv Radiol Med Image. 2016;1(1):103.]Search in Google Scholar
[16. Heinz-Peer G, Honigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol. 1999;173:15-22.10.2214/ajr.173.1.1039709210397092]Search in Google Scholar
[17. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194(6):1450-6010.2214/AJR.10.454720489083]Search in Google Scholar
[18. Boland GW, Lee M, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201-4.10.2214/ajr.171.1.96487899648789]Search in Google Scholar
[19. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrin. 2002;147(1):13-28.10.1530/eje.0.147001312088915]Search in Google Scholar
[20. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006 Jul;36(3):212-27.10.1053/j.semnuclmed.2006.03.00416762612]Open DOISearch in Google Scholar
[21. Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2012;1:58.10.3389/fonc.2011.00058335614022655253]Search in Google Scholar
[22. McDermott S, McCarthy CJ, Blake MA. Images of pheochromocytoma in adrenal glands. Gland surg. 2015;4(4):350.]Search in Google Scholar
[23. Maurea S, Mainenti PP, Ponsiglione A, Salvatore M. Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques. J Adv Radiol Med Image. 2016;1(1):103.]Search in Google Scholar
[24. Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448-54.10.2967/jnumed.108.058701472280719690028]Search in Google Scholar
[25. van Berkel A, Rao JU, Lenders JW, Pellegata NS, Kusters B, Piscaer I, Hermus AR, et al. Semiquantitative 123IMetaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. J Nucl Med. 2015;56(6):839-46.10.2967/jnumed.115.15481525883126]Search in Google Scholar
[26. Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc Natl Acad Sci USA. 2009;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27.10.1073/pnas.0907843106.Epub2009Aug27]Open DOISearch in Google Scholar
[27. Pisarek H, St Thepieñ T, Kubiak R, Pawlikowski M. Somatostatin receptors in human adrenal gland tumors–immunohistochemical study. Folia Histochem Cytobiol. 2008;46(3):345-51. doi: 10.2478/v10042-008-0051-2.10.2478/v10042-008-0051-219056539]Open DOISearch in Google Scholar
[28. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine’s view. J Pharm Pharm Sci. 2007;10(2):321s-7s]Search in Google Scholar
[29. Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol. 2015;2:159–68.10.2217/ije.14.40452614126257863]Search in Google Scholar
[30. Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39(12):1977–95.10.1007/s00259-012-2215-8471477222926712]Search in Google Scholar
[31. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–48.10.1007/s00259-010-1473-620461371]Search in Google Scholar
[32. Doknić M, Pekić S, Miljić D, Stojanović M, Soldatovic I, Petakov M. Etiology of hypopituitarism in adult patients: the experience of a single center database 1 in Serbian population. Int J Endocrinol. In press 2017. Available from: https://www.hindawi.com/journals/ije/aip/6969286/.10.1155/2017/6969286549408028702053]Open DOISearch in Google Scholar
[33. Novakovic Paro J, Mitrovic M, Medis Stojanoska M, Bajkin I, Icin T, Tomic D, et al. Epidemiological study of adrenal mass in our clinical centre. 11th European Congress of Endocrinology, Istanbul, Turkey 2009, Endocrine abstracts, vol 20, P 38.]Search in Google Scholar
[34. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014;38(1):7-41. doi: 10.1016/j.currproblcancer.2014.01.001. Epub 2014 Jan 15.10.1016/j.currproblcancer.2014.01.001.Epub201415]Open DOISearch in Google Scholar
[35. Kapoor A, Morris T, Rebello R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 2011;5:241–247.10.5489/cuaj.11135314703621801680]Search in Google Scholar
[36. Northcutt BG, Raman SP, Long C, Oshmyansky AR, Siegelman SS, Fishman EK, et al. MDCT of adrenal masses: can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?. Am J Roentgenol. 2013;201(4):834-9.10.2214/AJR.12.975324059372]Search in Google Scholar
[37. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD. Comparison of quantitative MRI and CT washout analysis for differentiation of adrenal pheochromocytoma from adrenal adenoma. Am J Roentgenol. 2016;206(6):1141-8.10.2214/AJR.15.1531827011100]Search in Google Scholar
[38. Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. Am J Roentgenol. 2013 Feb;200(2):370–37810.2214/AJR.12.912623345359]Search in Google Scholar
[39. Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [123I] metaiodobenzylguanidine and [111In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685-93.10.1210/jc.86.2.685]Search in Google Scholar